Merck & Co.’s Keytruda Stakes Another Adjuvant Flag, In RCC

 
• By Joseph Haas
  
Kidney cancer
Merck & Co. hopes to add adjuvant RCC to Keytruda's label
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D